(MENAFN Editorial) Market research future published a half cooked research report on global UTI treatment drugs market. The global market for UTI treatment drugs will approximately reach to $ 9.89 billion in 2023

Urinary tract infection (UTI treatment) is the infection of the lower or upper urinary tract due to bacteria such as Escherichia coli, Staphylococcus saprophyticus etc. The symptoms of UTI treatment are pain with urination, frequent urination and urination feeling despite having an empty bladder. The market driving factors for UTI treatment are female anatomy, sexual intercourse, diabetes, obesity etc. Due to the complications of female anatomy UTI treatment affects females more than males with the World Health Organization (WHO) estimating that approximately 50 % of women suffer from UTI treatment at some point of time in their lives resulting in more than 1 million hospitalizations per year. It has further been stated that 1% of boys and 3-8% of girls are diagnosed with UTI treatment and the annual cost of UTI treatment infections treatment to be greater than $1 billion.

The Global urinary tract infection (UTI treatment) drugs market is growing due to factors such as rise in hospital borne infections (nosocomial infections), child birth, old age, obesity, growing health awareness especially about women health etc.

However the fastest growth has been registered due to rising use of catheters (catheter associated UTI treatment).

Key players of Global UTI treatment Market:

Key players profiled in the report are Bayer AG, Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, AstraZeneca, Cipla Inc., Dr. Reddy's Laboratories Ltd., Johnson & Johnson GlaxoSmithKline and others.

Sample Report Available at .

Study objectives: To provide detail analysis of the market structure along with estimated future growth forecast for the next 6 years about various segments and sub-segments of the global UTI treatment market. To provide insights about factors affecting the market growth. To analyze the global UTI treatment market based on various factors - price analysis, supply chain analysis, Porters Five Force Analysis etc. To provide past and estimated future revenue of the market's segments and sub-segments with respect to four main geographies and their countries - Americas, Europe, Asia-Pacific along with Middle East & Africa. To provide country level analysis of the market with respect to the current market size and future growth prospect. To provide country level analysis of the market's segments which includes by drug class, clinical indications and by end user. To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies and drawing a competitive landscape of the market. To track and analyze developments which are competitive in nature such as joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments currently taking place in the global UTI treatment market.

The market constraints include growing drug resistance, unmet clinical needs, increasing incidence of chronic diseases resulting in chronic catheter use and low immunity etc.

Taking all these factors into consideration, the Global UTI treatment drugs market will approximately reach to $ 9.89 billion in 2023 from $ 8 billion in 2016 growing at a CAGR of 3.6%.

Segments: The Global UTI treatment Market is segmented on the basis of drug class which comprises of quinolones, aminoglycosides, β-lactam, azoles and others. On the basis of clinical indications this market is segmented into urethritis, cystitis, and pyelonephritis. On the basis of end users the market is segmented into hospitals and self-administered.

Regional analysis- U.S. accounts for the largest market share of the global UTI treatment market followed by Europe. However Europe has a greater hospitalization rate than the U.S. despite the U.S. having a large spending on healthcare. The regulatory changes in the U.S. such as implementation of Affordable Care Act and Hospital Readmissions Reduction Program coupled with Medicare initiative to penalize unnecessary patient readmissions is expected to take a toll on the U.S UTI treatment market. Asia pacific will be the fastest growing market and the growth will be led by China, and India as these nations have huge population and the low cost of UTI treatment drugs.

Browse complete report at .

Table of Content

1 Introduction

1.1 Definition

1.2 Scope of Study

1.3 Research Objective

1.4 Assumptions & Limitations

1.5 Market Structure:

2 Research Methodology

2.1 Research Process

2.2 Primary Research

2.3 Secondary Research

3 Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Challenges

3.5 Macroeconomic Indicators

4 Market Factor Analysis

4.1 Porter's Five Forces Model

4.1.1 Bargaining Power of Suppliers

4.1.2 Bargaining Power of Customer

4.1.3 Intensity of Competitor's

4.1.4 Threat of New Entrants

Media Contact
Company Name: Market Research Future
Contact Person: Akash Anand
Email:
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune -
City: Pune
State: Maharashtra
Country: India
Website:

MENAFN1512201700703268ID1096237569